 Randomization implementation: Enrollment of patients, assessing eligibility and obtaining informed consent will be carried out by one of the investigators S.S. Sidhu or O. Goyal, BC Sharma Study Intervention: The patients will be randomized to receive either placebo or LOLA at dose of 30 grams daily, by intravenous infusion over 24 hours. The study drugs and placebo will be provided by Win Medicare Pvt Ltd., 1400, Modi tower, 98, Nehru Place, New Delhi- 110019. LOLA will be supplied as ampoules each ampoule containing 5 grams LOLA in 10 ml clear solution. Six ampoules i.e 30 g of LOLA will be infused over 24 hours. The placebo vials 10 ml sterile water in each vial will be identically supplied and infused. The dose of LOLA 30 g in 24 hours was based on previous studies, showing the efficacy of this dose in decreasing ammonia levels 17,26,28. Both groups shall receive treatment for 5 days. Patients in both the groups who continue to have hepatic encephalopathy at the end of study period 5 days, will receive standard of care treatment, and would be counseled about liver transplant. 